Summary
Pfizer Inc. (PFE) filed an 8-K on April 19, 2005, to report its first-quarter 2005 financial results and to disclose significant impairment charges. The company announced its Q1 2005 financial performance via a press release, incorporated by reference as an exhibit. A substantial portion of this filing addresses material impairments related to the drug Bextra, a selective Cox-2 inhibitor pain reliever. Following the decision to suspend sales of Bextra, announced earlier in April 2005, Pfizer determined that certain intangible assets associated with the drug have become impaired. This resulted in pre-tax charges of $1.213 billion in the first quarter of 2005. These charges encompass write-downs of developed technology rights, machinery and equipment, inventory, and costs associated with administering the sales suspension. Investors should note the significant financial impact of this product discontinuation on the company's first-quarter results.
Key Highlights
- 1Pfizer announced its first-quarter 2005 financial results via press release filed as Exhibit 99.
- 2The company recorded material impairment charges totaling $1.213 billion pre-tax in Q1 2005.
- 3These charges are primarily due to the suspension of sales for the drug Bextra.
- 4Impairment includes $1.145 billion for Bextra's intangible assets (developed technology rights).
- 5Additional charges include $10 million for machinery and equipment write-offs.
- 6Inventory write-offs amounted to $56 million.
- 7Costs related to administering the sales suspension were $2 million.